FluoroPharma Medical, Inc. engages in the discovery, development, and commercialization of proprietary medical diagnostic imaging products. The company is headquartered in Montclair, New Jersey and currently employs 4 full-time employees. The company went IPO on 2008-08-18. The firm is focused on the development of cardiovascular imaging agents that detect and assess acute and chronic forms of coronary artery disease (CAD). The company has two clinical-stage molecular imaging pharmaceutical product candidates: 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). BFPET program employs a (18F)-labeled cationic lipophilic tetraphenylphosphonium ion as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD. The company measures the extent and severity of cardiovascular disease through the detection of ischemic and infarcted myocardial tissue. CardioPET program employs Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid as a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with CAD.
最新の財務諸表(Form-10K)によると、FluoroPharma Medical Incの総資産は$0で、純損失は$-2です。
FPMIの主要な財務比率は何ですか?
FluoroPharma Medical Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
FluoroPharma Medical Incの収益はセグメントまたは地域別にどのように分けられていますか?
FluoroPharma Medical Inc の最大収益セグメントは Nursing Care Career で、最新の利益発表における収益は 19,320,000,000 です。地域別に見ると、Japan が FluoroPharma Medical Inc の主要市場であり、収益は 51,567,000,000 です。
FluoroPharma Medical Incは収益を上げていますか?
いいえ、最新の財務諸表によると、FluoroPharma Medical Incの純損失は$-2です。